ERO1A and cancer: Furthermore, the dispensability of ERO1A in healthy cells and the lack of an overt phenotype of ERO1A-devoid murine models, in stark contrast with the relevance of ERO1A in TNBC angiogenesis, make ERO1A an ideal target for TNBC therapy so an ERO1A inhibitor might be a promising cancer drug with a unique broad antiangiogenic feature.